STOCK TITAN

IN8bio Inc - INAB STOCK NEWS

Welcome to our dedicated news page for IN8bio (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IN8bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IN8bio's position in the market.

Rhea-AI Summary
IN8bio, Inc. announced positive data presentations at the SITC Annual Meeting, showcasing Phase 1 trial results for INB-200 and pre-clinical insights on their iPSC gamma-delta T cell platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none
-
Rhea-AI Summary
IN8bio, Inc. announces its upcoming Research & Development Day on October 12, 2023, featuring presentations by clinical thought leaders and upcoming data releases at fall medical meetings. The event will provide insights into IN8bio's clinical and scientific programs, including gamma-delta T cell therapies. Positive impact on stock price expected from potential catalysts and key opinion leader support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences
-
Rhea-AI Summary
IN8bio, Inc. CEO to participate in panel presentation at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.62%
Tags
conferences
Rhea-AI Summary
IN8bio expands DeltEx DRI platform with newly granted patents for CAR-T and CPIs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
none
-
Rhea-AI Summary
IN8bio CEO to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) reported positive Phase 1 data for INB-200 at the ASCO Annual Meeting, with 100% of treated patients exceeding historical median progression-free survival. Phase 2 trial for INB-400 in glioblastoma multiforme (GBM) to begin enrollment in the second half of 2023. Promising preclinical data in ovarian cancer presented at ASGCT Annual Meeting. Financial results for Q2 2023 showed increased R&D expenses and a net loss of $7.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
IN8bio Inc

Nasdaq:INAB

INAB Rankings

INAB Stock Data

48.05M
24.46M
15.97%
37.34%
0.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
New York

About INAB

in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.